Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
Rhea-AI Summary
Kura Oncology (Nasdaq: KURA) will present updated long-term follow-up data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced clear cell renal cell carcinoma at the 2026 Kidney Cancer Research Summit in Boston on July 24, 2026.
The company is also enrolling a global randomized Phase 1b trial comparing the combination versus cabozantinib alone to inform a planned registrational Phase 3 study in 2028 and will host a virtual investor call on July 27, 2026.
Positive
- None.
Negative
- None.
News Market Reaction – KURA
In the Jul 14 session, KURA gained 3.02%, reflecting a moderate positive market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 11 | AML clinical data | Positive | +2.1% | Encouraging long-term KOMET-007 results for ziftomenib plus 7+3 in AML. |
| Jun 05 | Inducement option grants | Neutral | -0.3% | Stock option inducement awards to new employees under 2023 Inducement Option Plan. |
| Jun 03 | KRAS platform update | Positive | -3.5% | Preliminary Phase 1a darlifarnib + adagrasib data and combination platform plans. |
| Jun 02 | AML combo data | Positive | -0.7% | Updated KOMET-007 ziftomenib + venetoclax/azacitidine results in R/R NPM1-mutated AML. |
| May 26 | KRAS G12C data | Positive | -7.5% | Phase 1a FIT-001 darlifarnib + adagrasib data in KRAS G12C-mutated solid tumors. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical updates have often coincided with negative share moves, suggesting a recurring divergence between data strength and immediate price reaction.
Key Terms
vegfr-targeted therapy medical
vegf-tki medical
mtorc1 medical
farnesyl transferase inhibitor medical
rule 10b5-1 trading plan regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients –
– Updated data expected to support darlifarnib’s potential to enhance VEGFR-targeted therapy in ccRCC –
– Global randomized Phase 1b study comparing darlifarnib plus cabozantinib versus cabozantinib alone is ongoing –
– Results continue to support darlifarnib as a precision combination agent across multiple targeted therapy classes –
– Virtual investor call on July 27, 2026 at 5:00 a.m. PT / 8:00 a.m. ET –
SAN DIEGO, July 14, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that updated Phase 1a results from the ongoing FIT-001 Phase 1a/1b clinical trial (NCT06026410) evaluating darlifarnib in combination with cabozantinib in advanced renal cell carcinoma (RCC) will be featured in an oral presentation at the 2026 Kidney Cancer Research Summit (KCRS) in Boston.
The presentation will highlight long-term follow-up results in heavily pretreated cabozantinib-naïve patients with refractory RCC, providing further evidence of darlifarnib’s potential as a combination agent with VEGFR-targeted therapies, a widely used treatment approach in this patient population. RCC is the most common form of kidney cancer, and clear cell RCC (ccRCC) is the most common histology in RCC, accounting for more than 61,000 new cases in the U.S. each year.1
“Despite meaningful advances in the treatment of renal cell carcinoma, there remains a significant need for combination strategies capable of delivering deeper and more durable responses,” said Mollie Leoni, M.D., Chief Medical Officer of Kura Oncology. “The updated FIT-001 data will further inform the potential of darlifarnib plus cabozantinib as a precision combination strategy in advanced ccRCC. More broadly, Kura’s KCRS presentation builds on the growing body of clinical evidence supporting darlifarnib’s mechanism of action across VEGF-TKI, KRAS and PI3Ka inhibitor combinations, supporting darlifarnib’s potential to enhance clinical activity of these targeted-therapy backbones.”
The KCRS presentation adds to the FIT-001 RCC results presented at ESMO 2025 and additional findings in cabozantinib-exposed ccRCC patients presented at 2026 IKCS: Europe.
Kura is currently enrolling patients in the U.S. and E.U. in the randomized Phase 1b dose-optimization portion of FIT-001 in cabozantinib-naïve, refractory, advanced ccRCC. The randomized Phase 1b portion is evaluating darlifarnib plus cabozantinib versus cabozantinib alone and is designed to inform selection of a recommended Phase 3 dose for a registrational study planned for 2028.
The KCRS presentation represents another step in Kura's broader strategy to establish darlifarnib as a precision combination agent capable of enhancing multiple targeted therapy classes through inhibition of adaptive mTORC1 signaling. The first planned expansion is expected to evaluate darlifarnib in combination with daraxonrasib in previously treated RAS-mutated pancreatic ductal adenocarcinoma.
2026 KCRS Presentation Details
Title: Farnesyl transferase inhibitor (FTI) darlifarnib combined with cabozantinib in renal cell carcinoma (RCC): Updated phase 1a results from FIT-001
Date: July 24, 2026
Time: 3:05 p.m. – 3:45 p.m. ET
Virtual Investor Event
Kura will host a webcast and conference call on July 27, 2026 at 5:00 a.m. PT / 8:00 a.m. ET featuring management and Adanma Ayanambakkam, M.D., M.S., Assistant Professor of Hematology Oncology and Director of Genitourinary Medical Oncology Research, Stephenson Cancer Center, University of Oklahoma Health Sciences Center. The live webcast and replay will be available on the Company’s website at www.kuraoncology.com under the Investors tab in the Events and Presentations section.
About darlifarnib
Darlifarnib is a next-generation farnesyl transferase inhibitor (FTI) designed to inhibit farnesylation of RHEB and suppress mTORC1 signaling, a pathway implicated in adaptive signaling across multiple targeted therapy settings. By suppressing adaptive mTORC1 signaling, darlifarnib is designed to counter a key mechanism of resistance to targeted therapies, with the goal of enhancing the depth and durability of response across multiple targeted therapy classes.
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things, statements regarding Kura’s anticipated presentation of data and results at KCRS, the potential of darlifarnib to enhance the activity of cabozantinib and other VEGFR-targeted therapies and to serve as a combination partner for targeted therapies more broadly, and ongoing and planned clinical trials of darlifarnib in combination with cabozantinib and other targeted therapies. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, and other interactions with regulatory bodies, and other risks associated with the process of discovering, developing, and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Kura faces, please refer to Kura’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Conflict of Interest Disclosure
Dr. Ayanambakkam's disclosures include consulting or advisory roles with AVEO, Pfizer/Astellas; Johnson & Johnson; Kura Oncology: Travel, Accommodations, Expenses, and Research Funding; and Regeneron.
1 Ozay ZI, Jo Y, Galarza Fortuna G, et al. Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the US. JAMA Netw Open. 2025;8(3):e251201. doi:10.1001/jamanetworkopen.2025.1201
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
